Shares of medical device company Artivion (NYSE:AORT) fell 11.2% in the morning session after the company reported weak fourth-quarter 2024 results, as both revenue and EPS missed Wall Street's ...

Artivion (NYSE:AORT – Get Free Report) had its target price reduced by equities research analysts at Stifel Nicolaus from $33 ...

It's been a mediocre week for Artivion, Inc. ( NYSE:AORT ) shareholders, with the stock dropping 13% to US$25.42 in ...

Q4 2024 Earnings Call Transcript February 24, 2025 Artivion, Inc. misses on earnings expectations. Reported EPS is $-0.39 EPS ...

Artivion, Inc. (NYSE:AORT – Get Free Report)’s stock price gapped down before the market opened on Tuesday following a dissappointing earnings announcement. The stock had previously closed at $27.85, ...

Stifel lowered the firm’s price target on Artivion (AORT) to $30 from $33 and keeps a Buy rating on the shares after Q4 consensus sales ...

In the latest quarter, 4 analysts provided ratings for Artivion (NYSE:AORT), showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings, shedding ...

Needham lowered the firm’s price target on Artivion (AORT) to $32 from $34 and keeps a Buy rating on the shares after its Q4 results. The company’s constant currency revenue growth slowed to 3 ...

Highlights: Achieved revenue of $97.3 million in the fourth quarter of 2024 versus $93.7 million in the fourth quarter of 2023, an increase of 4% ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Artivion Inc (Symbol: AORT) entered into oversold territory, hitting an RSI reading of 21.9 ...

A downtrend has been apparent in Artivion (AORT) lately with too much selling pressure. The stock has declined 18.6% over the ...